IBSA Institut Biochimique SA is a privately owned pharmaceutical company founded in Lugano in 1945. It started to develop its specific identity in 1985, when the current management took over, redefining its strategy and focusing on developing technologies that improve the quality of existing therapeutic solutions. Today, it is present on 5 continents and over 90 countries. The Group now counts on 20 subsidiaries in Europe, China and USA, and boasts a product portfolio covering 10 therapeutic areas. The company employs over 2,500 people, distributed among its headquarters, subsidiaries and manufacturing sites. IBSA is one of the four largest operators worldwide in the area of Reproductive Medicine and one of the world's leaders in hyaluronic acid-based products. Therapeutic areas: 🔹 Reproductive Medicine 🔹 Endocrinology 🔹 Pain and Inflammation 🔹 Osteoarticular 🔹 Aesthetic Medicine 🔹 Dermatology 🔹 Uro-gynaecology 🔹 Cardiometabolic 🔹 Respiratory 🔹 Consumer Health
| Website | http://www.ibsagroup.com/ |
| Revenue | $540.1 million |
| Employees | 1,114 (818 on RocketReach) |
| Founded | 1945 |
| Phone | +41 58 360 10 00 |
| Industry | Pharmaceutical Manufacturing, Biotechnology, Science and Engineering, Pharmaceutical, Health Care, Therapeutics |
| Keywords | Healthcare, Pharmaceutical Products, Drug Development, Medical Technology, Specialty Pharmaceuticals, Biotechnology, Research And Development, Drug Manufacturing, Generic Drugs, Clinical Trials, Quality Control, Sales And Marketing, Contract Manufacturing, Regulatory Affairs, Supply Chain, Distribution, Private Equity |
| Competitors | Roche, Boehringer Ingelheim, AstraZeneca, Teva Pharmaceuticals, Novartis, Ferring Pharmaceuticals, Sandoz, Baxter International Inc., GSK, Mylan Belgium +38 more (view full list) |
Looking for a particular IBSA Group employee's phone or email?
The IBSA Group annual revenue was $540.1 million in 2026.
Luca Crippa is the Chief Commercial Officer and Chairman of the Executive Committee of IBSA Group.
818 people are employed at IBSA Group.